Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion

NCT06333899 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT06333899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06333899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
August 3, 2025
Completion date
June 1, 2035
Enrollment
15 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, diffuse intrinsic pontine glioma, diffuse midline glioma, h3k27-altered, glioblastoma, glioblastoma multiforme, high grade glioma, infant type hemispheric glioma, who grade iii glioma, who grade iv glioma